Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across biomedical AI, cancer, cardiovascular diseases, inflammation, immunity, age-related, rare and infectious diseases.

          Learn more

        • Biomedical AI
        • Cancer Innovations
        • Cardiovascular Research
        • Healthy Ageing
        • Infection & Immunity
        • Inflammation
        • Rare Diseases & Gene Therapy
        • Laboratories
        • Diseases
        • Expertises
        • Breakthroughs
        • Technologies
          • Clinical Translation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
        • Community and research
  • Careers & students
        • Careers & Students

          Postdoctoral and postgraduate students can work alongside world-leading medical researchers within state-of-the-art research facilities.

        • Career Opportunities
        • Student Opportunities
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
          • Healthy Recipes
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
          • Statements
        • Real stories
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
          • Animals in research
        • Contact
  • Donate
    Centenary Institute > News > COVID-19 research targets human enzymes

COVID-19 research targets human enzymes

Date time 14 May, 2020
News Type News type Media release
Centenary Institute researchers have examined the critical role of human enzymes and the coronavirus in a newly published scientific review article that explores potential strategies for COVID-19 disease treatment and management.

The review article published in the prestigious ‘Journal of Diabetes’, seeks to explain how the human enzyme dipeptidyl peptidase (DPP4), which is a driver of diabetes severity, could be exacerbating COVID-19.

“COVID-19 is more severe in people who have type 2 diabetes, obesity and related chronic diseases,” says Professor Mark Gorrell (Head of the Centenary Institute Liver Enzymes in Metabolism and Inflammation Program) and senior author of the review article.

“We also see more DPP4 made in people with diabetes, obesity and related chronic diseases. Drugs that target DPP4 enzyme activity are regularly taken by many people for type 2 diabetes. Such drugs may have immune system and cardioprotective effects that could be beneficial in COVID-19 cases,” he says.

The review article notes that DPP4, which is known to be the key receptor for the MERS-coronavirus (Middle East respiratory syndrome) might also be an additional or alternate port of entry for SARS-CoV-2 into human cells.

“COVID-19 is caused by the SARS-CoV-2 coronavirus, which is similar to SARS-CoV and MERS-CoV. Each of these viruses attach to and enter human cells by binding to specific human enzymes,” says Professor Gorrell.

“Recent research suggests that SARS-CoV-2 can bind to both DPP4 and the ACE2 enzyme and so have two ways to infect our lungs and gut. Once we fully understand this process, we may be able to develop a drug that can help disrupt this viral activity,” he says.

Professor Gorrell, an expert in human proteases (enzymes that break down proteins) has recently launched a new research program in response to the growing COVID-19 pandemic.

“TMPRSS2 (Transmembrane protease, serine 2) is essential for SARS-CoV and SARS-CoV-2 infection. This protease activates the viral protein on the coronavirus necessary for virus cell entry at the start of viral infection in the human body,” he says.

“We are looking to develop a selective TMPRSS2 inhibitor that is both effective and very safe using our expertise and a unique drug screening approach. The successful development of such an inhibitor could be utilised as a novel therapy for both past and current, and possibly future, SARS-CoV coronaviruses.”

“I’m optimistic that our research will contribute meaningfully to the global COVID-19 health response,” he says.

Read the full media release here.

Further Information on the Centenary Institute’s coronavirus activity can be found here.

Themes

  • Inflammation

    Inflammation

Media enquires

For all media and interview enquiries, please contact Alison Mendel

Phone number Phone Number +61 402 770 403

Email Email t.crawshaw@centenary.org.au

Media Release

Download

Recent Stories

  • New platform to evolve proteins for better therapies

    Researchers from the Centenary Institute, in collaboration with the University of Sydney, have developed a powerful new tool to evolve proteins directly within mammalian cells, offering a more effective way to design medical treatments tailored to the human body.
    News Type: Media release
    Date 08 May 2025
  • Turning off protein may help prevent liver cancer

    New research from the Centenary Institute has found that switching off a specific protein in liver cells may help prevent the early development of liver cancer.
    News Type: Media release
    Date 16 Apr 2025
  • Event shines spotlight on genetic heart disease in young people

    The Centenary Institute has hosted a community event, titled ‘A Needle in a Haystack: Unlocking the Secrets of Genetic Heart Conditions’. The event aimed to advance understanding of inherited heart disease and sudden cardiac death in young people.
    News Type: Community
    Date 10 Apr 2025
  • Finding answers for sudden cardiac death in young people

    Each week in Australia, up to three young people die suddenly and unexpectedly from sudden cardiac death, often due to an undiagnosed genetic heart condition. These conditions typically go unnoticed until tragedy strikes, leaving families devastated and searching for answers.
    News Type: Media release
    Date 02 Apr 2025

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram